Belén Garijo, Merck KGaA CEO (Arne Dedert/picture-alliance/dpa/AP Images)
March 27, 2023 03:28 PM EDT
Deals
Pharma

Mer­ck KGaA takes back con­trol of PD-L1 can­cer drug as Pfiz­er al­liance ends

Paul Schloesser

Associate Editor

Mer­ck KGaA re­port­ed Mon­day that it had re­gained full rights to its PD-L1 an­ti­body Baven­cio af­ter a near­ly 10-year al­liance with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times